To date, companies have tended to use more established delivery systems such as lipid nanoparticles, viral vectors or electroporation, and although these can produce good immune responses, they can also cause unwanted side effects such as the release of systemic inflammatory cytokines, causing the patient to feel unwell, or in the case of electroporation, are very expensive and complicated to administer. It has been reported that lipid nanoparticle supply is restricted due to shortages in both lipid components and assembly technology at scale.
Nuvec® is an alternative to these existing systems.
To see our proof of concept data contact us here.
The diagram below shows the end-to-end mode of action for Nuvec® as it delivers DNA/RNA to antigen presenting cells.